



Joint Symposium 2

EANM–EORTC Joint Symposium – Oncology and Theranostics Committee

Sunday, October 18, 15:00–16:30

Session Title

Design and Conduct of Clinical Trials: How to Generate Evidence for RLTs

Chairpersons

Karolien Goffin (Leuven, Belgium)

Matthias Preusser (Vienna, Austria)

Programme

15:00–15:20 **Christophe Deroose** (Leuven, Belgium): Current RLT Activities of the EORTC

15:20–15:45 **Nathalie L. Albert** (Munich, Germany): Evidence-Based Evaluation of RLT Targets: THERASCOPE

15:45–16:10 **Matthias Preusser** (Vienna, Austria): Challenges and Opportunities of Multinational Trial Conduct

16:10–16:30 **Michael S. Hofman** (Melbourne, Australia): Appropriate Endpoints for RLT Trials

Educational Objectives

1. Gain insight into current RLT academic research activities.
2. Learn how to apply evidence-based frameworks such as THERASCOPE for the evaluation and prioritisation of RLT targets.
3. Understand the specific challenges and opportunities associated with conducting multinational clinical trials.
4. Understand the selection of appropriate clinical endpoints for RLT trials, with a focus on generating robust, regulatory-relevant evidence to support clinical development and implementation.

Summary

Radioligand therapies are rapidly transforming the landscape of oncological treatment, creating an urgent need for high-quality clinical evidence to support their safe and effective integration into clinical practice. This joint EANM–EORTC symposium brings together international experts to discuss key methodological aspects of RLT clinical trial design and execution, highlighting current EORTC initiatives, structured approaches for evidence-based target assessment, and practical considerations in conducting multinational trials. The session also addresses the critical issue of endpoint selection in RLT studies, balancing biological relevance, patient benefit, and regulatory expectations to accelerate evidence generation and advance the field of radioligand therapy.

Key Words

Theranostics; Clinical Trial Design; Evidence Generation; EORTC; THERASCOPE